DMD Simcyp

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
QUICK SEARCH:   [advanced]


     

Drug Metabolism and Disposition Fast Forward
First published on June 25, 2007; DOI: 10.1124/dmd.107.016196

0090-9556/07/3509-1657-1663$20.00
DMD 35:1657-1663, 2007

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
dmd.107.016196v1
35/9/1657    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kassahun, K.
Right arrow Articles by Wenning, L. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kassahun, K.
Right arrow Articles by Wenning, L. A.

Metabolism and Disposition in Humans of Raltegravir (MK-0518), an Anti-AIDS Drug Targeting the Human Immunodeficiency Virus 1 Integrase Enzyme

Kelem Kassahun, Ian McIntosh, Donghui Cui, David Hreniuk, Shelia Merschman, Kenneth Lasseter, Neal Azrolan, Marian Iwamoto, John A. Wagner, and Larissa A. Wenning

Merck Research Laboratories, West Point, Pennsylvania (K.K., I.M., D.C., S.M., L.A.W.), Upper Gwynedd, Pennsylvania (N.A.), and Rahway, New Jersey (D.H., M.I., J.A.W.); and SFBC International, Miami, Florida (K.L.)

Raltegravir is a potent human immunodeficiency virus 1 (HIV-1) integrase strand transfer inhibitor that is being developed as a novel anti-AIDS drug. The absorption, metabolism, and excretion of raltegravir were studied in healthy volunteers after a single oral dose of 200 mg (200 µCi) of [14C]raltegravir. Plasma, urine, and fecal samples were collected at specified intervals up to 240 h postdose, and the samples were analyzed for total radioactivity, parent compound, and metabolites. Radioactivity was eliminated in substantial amounts in both urine (32%) and feces (51%). The elimination of radioactivity was rapid, since the majority of the recovered dose was attributable to samples collected through 24 h. In extracts of urine, two components were detected and were identified as raltegravir and the glucuronide of raltegravir (M2), and each accounted for 9% and 23% of the dose recovered in urine, respectively. Only a single radioactive peak, which was identified as raltegravir, was detected in fecal extracts; raltegravir in feces is believed to be derived, at least in part, from the hydrolysis of M2 secreted in bile, as demonstrated in rats. The major entity in plasma was raltegravir, which represented 70% of the total radioactivity, with the remaining radioactivity accounted for by M2. Studies using cDNA-expressed UDP-glucuronosyltransferases (UGTs), form-selective chemical inhibitors, and correlation analysis indicated that UGT1A1 was the main UGT isoform responsible for the formation of M2. Collectively, the data indicate that the major mechanism of clearance of raltegravir in humans is UGT1A1-mediated glucuronidation.

Address correspondence to: Dr. Kelem Kassahun, Department of Drug Metabolism, WP75B-200, Merck Research Laboratories, P.O. Box 4, West Point, PA 19486. E-mail: kelem_kassahun{at}merck.com




This article has been cited by other articles:


Home page
 Antimicrob. Agents Chemother.Home page
W. D. Hanley, L. A. Wenning, A. Moreau, J. T. Kost, E. Mangin, T. Shamp, J. A. Stone, K. M. Gottesdiener, J. A. Wagner, and M. Iwamoto
Effect of Tipranavir-Ritonavir on Pharmacokinetics of Raltegravir
Antimicrob. Agents Chemother., July 1, 2009; 53(7): 2752 - 2755.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
L. A. Wenning, W. D. Hanley, D. M. Brainard, A. S. Petry, K. Ghosh, B. Jin, E. Mangin, T. C. Marbury, J. K. Berg, J. A. Chodakewitz, et al.
Effect of Rifampin, a Potent Inducer of Drug-Metabolizing Enzymes, on the Pharmacokinetics of Raltegravir
Antimicrob. Agents Chemother., July 1, 2009; 53(7): 2852 - 2856.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
M. Iwamoto, W. D. Hanley, A. S. Petry, E. J. Friedman, J. T. Kost, S. A. Breidinger, K. C. Lasseter, R. Robson, N. M. Lunde, L. A. Wenning, et al.
Lack of a Clinically Important Effect of Moderate Hepatic Insufficiency and Severe Renal Insufficiency on Raltegravir Pharmacokinetics
Antimicrob. Agents Chemother., May 1, 2009; 53(5): 1747 - 1752.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
R. Laufer, O. G. Paz, A. Di Marco, F. Bonelli, E. Monteagudo, V. Summa, and M. Rowley
Quantitative Prediction of Human Clearance Guiding the Development of Raltegravir (MK-0518, Isentress) and Related HIV Integrase Inhibitors
Drug Metab. Dispos., April 1, 2009; 37(4): 873 - 883.
[Abstract] [Full Text] [PDF]

Home page
 J. Virol.Home page
D. N. Vatakis, C. C. Nixon, G. Bristol, and J. A. Zack
Differentially Stimulated CD4+ T Cells Display Altered Human Immunodeficiency Virus Infection Kinetics: Implications for the Efficacy of Antiviral Agents
J. Virol., April 1, 2009; 83(7): 3374 - 3378.
[Abstract] [Full Text] [PDF]

Home page
 Int J STD AIDSHome page
T W Mahungu, M A Johnson, A Owen, and D J Back
The impact of pharmacogenetics on HIV therapy
Int J STD AIDS, March 1, 2009; 20(3): 145 - 151.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
M. Iwamoto, L. A. Wenning, A. S. Petry, M. Laethem, M. De Smet, J. T. Kost, S. A. Breidinger, E. C. Mangin, N. Azrolan, H. E. Greenberg, et al.
Minimal Effects of Ritonavir and Efavirenz on the Pharmacokinetics of Raltegravir
Antimicrob. Agents Chemother., December 1, 2008; 52(12): 4338 - 4343.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
M. S. Anderson, T. N. Kakuda, W. Hanley, J. Miller, J. T. Kost, R. Stoltz, L. A. Wenning, J. A. Stone, R. M. W. Hoetelmans, J. A. Wagner, et al.
Minimal Pharmacokinetic Interaction between the Human Immunodeficiency Virus Nonnucleoside Reverse Transcriptase Inhibitor Etravirine and the Integrase Inhibitor Raltegravir in Healthy Subjects
Antimicrob. Agents Chemother., December 1, 2008; 52(12): 4228 - 4232.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
L. A. Wenning, E. J. Friedman, J. T. Kost, S. A. Breidinger, J. E. Stek, K. C. Lasseter, K. M. Gottesdiener, J. Chen, H. Teppler, J. A. Wagner, et al.
Lack of a Significant Drug Interaction between Raltegravir and Tenofovir
Antimicrob. Agents Chemother., September 1, 2008; 52(9): 3253 - 3258.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
R. T. Steigbigel, D. A. Cooper, P. N. Kumar, J. E. Eron, M. Schechter, M. Markowitz, M. R. Loutfy, J. L. Lennox, J. M. Gatell, J. K. Rockstroh, et al.
Raltegravir with Optimized Background Therapy for Resistant HIV-1 Infection
N. Engl. J. Med., July 24, 2008; 359(4): 339 - 354.
[Abstract] [Full Text] [PDF]

Home page
 J Clin PharmacolHome page
M. Iwamoto, J. T. Kost, G. C. Mistry, L. A. Wenning, S. A. Breidinger, T. C. Marbury, J. A. Stone, K. M. Gottesdiener, D. M. Bloomfield, and J. A. Wagner
Raltegravir Thorough QT/QTc Study: A Single Supratherapeutic Dose of Raltegravir Does Not Prolong the QTcF Interval
J. Clin. Pharmacol., June 1, 2008; 48(6): 726 - 733.
[Abstract] [Full Text] [PDF]

Home page
 J Clin PharmacolHome page
M. Iwamoto, K. Kassahun, M. D. Troyer, W. D. Hanley, P. Lu, A. Rhoton, A. S. Petry, K. Ghosh, E. Mangin, E. P. DeNoia, et al.
Lack of a Pharmacokinetic Effect of Raltegravir on Midazolam: In Vitro/In Vivo Correlation
J. Clin. Pharmacol., February 1, 2008; 48(2): 209 - 214.
[Abstract] [Full Text] [PDF]


Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
Molecular Interventions Drug Metabolism and Disposition

Copyright © 2007 by the American Society for Pharmacology and Experimental Therapeutics.